Small-cell lung cancer (SCLC) is one of the most aggressive and deadly types of cancer, often linked to smoking. Although it ...

Purdue University scientists have identified the Supinoxin small-molecule drug as a possible new therapy for small-cell lung ...

Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission ...

Ivonescimab plus chemotherapy improved survival in advanced squamous NSCLC vs tislelizumab and chemotherapy in a phase 3 ...

During a live event, Xiuning Le, MD, PhD, discussed updated intracranial efficacy, overall survival, and safety of ...

Immunai will generate a publicly accessible multi-omic dataset for a Parker Institute cohort of over 1,000 cancer patients.

Akeso and Summit Therapeutics’ giant-killing, PD-1xVEGF bispecific antibody ivonescimab has posted another phase 3 trial win ...

Prostate cancer remains one of the most significant health concerns for men worldwide, with detection and treatment options ...

Tumor-infiltrating clonal hematopoiesis (TI-CH) increased the risk of disease recurrence or death among patients with early ...

Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission expected in 1H-2026 ...

The data from the Phase III LUNAR trial, which assessed the device’s treatment efficacy and safety, supported the approval.